Mayank MD - EFFECTOR Therapeutics Chief Officer
Executive
Mayank MD is Chief Officer of EFFECTOR Therapeutics
| Age | 46 |
| Phone | 858 925 8215 |
| Web | https://effector.com |
EFFECTOR Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.8333) % which means that it has lost $0.8333 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (9.4656) %, meaning that it generated substantial loss on money invested by shareholders. EFFECTOR Therapeutics' management efficiency ratios could be used to measure how well EFFECTOR Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | EXECUTIVE Age | ||
| Riccardo Panicucci | NRx Pharmaceuticals | 63 | |
| Matthew Duffy | NRx Pharmaceuticals | 62 | |
| William Scheessele | Humacyte | 53 | |
| Shamik MD | Humacyte | 52 | |
| Yang MD | Humacyte | 59 | |
| Harold Alterson | Humacyte | N/A | |
| SPHR GPHR | Humacyte | N/A | |
| Michael Abrams | NRx Pharmaceuticals | 55 | |
| Sabrina Osborne | Humacyte | N/A | |
Management Performance
| Return On Equity | -9.47 | |||
| Return On Asset | -0.83 |
EFFECTOR Therapeutics Leadership Team
Elected by the shareholders, the EFFECTOR Therapeutics' board of directors comprises two types of representatives: EFFECTOR Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EFFECTOR. The board's role is to monitor EFFECTOR Therapeutics' management team and ensure that shareholders' interests are well served. EFFECTOR Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EFFECTOR Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Siegfried Reich, CoFounder Advisor | ||
| Mayank MD, Chief Officer | ||
| Michael MBA, Chief Officer | ||
| Alana MBA, Chief Officer | ||
| Premal MD, Chief Officer | ||
| Davide Ruggero, CoFounder Board | ||
| Douglas MD, Chief Officer | ||
| Stephen Worland, President CEO | ||
| Kevan Shokat, CoFounder Board |
EFFECTOR Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is EFFECTOR Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -9.47 | |||
| Return On Asset | -0.83 | |||
| Number Of Shares Shorted | 18.44 K | |||
| EBITDA | (33.73 M) | |||
| Net Income | (35.81 M) | |||
| Total Debt | 19.45 M | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (29.55 M) | |||
| Earnings Per Share | (0.91) X | |||
| Number Of Employees | 14 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in EFFECTOR Pink Sheet
If you are still planning to invest in EFFECTOR Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EFFECTOR Therapeutics' history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |